Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: question for the board, looking for the most logical answer, let's see who has
FWIW  his shareholders letter indicates that he was surprised.
"The market price for PTSC shares experienced some exciting ups and perplexing downs during the year".
which to me as a shareholder tells me that in his honest opinion he never expected the share price to go that low. If warrants are being sold in the 10's of millions then share price will obviously come down and come down a lot. The only way it will not go all the way down is if someone buys the shares as they are being sold. If someone known to PTSC is buying shares then the price should have been predictable hence no statement about "perplexing" share price lows. If Pohl was expecting retail shareholders to buy then PTSC needs more publicity, or was he expecting existing shareholders to repurchase with dividends.

I hope he tries to clarify this and also issues some level of guidance for PTSC in his upcoming letter.
Share
New Message
Please login to post a reply